Table 4.

Multivariate Cox proportional-hazard regression analysis for assessing the risk of cancer and of death related to different systemic sclerosis (SSc)-autoantibodies. Abbreviations: ANA (anti-nuclear antigens); BMI (body mass index); CI (confidence interval); HR (hazard ratio); RNAPIII (RNA polymerase III); RNP (ribonucleoproteins); Scl-70 (topoisomerase-I); SES (socioeconomic status).

	Risk of cancer development in SSc-Patients			Risk of death in SSc-patients with cancer
Autoantibody	HRa	95%CI	p-value	HRa	95%CI	p-value
ANA
Overall risk	0.84	0.66 to 1.08	0.1666	0.64	0.50 to 0.83	0.0007
Risk after SSc diagnosis	0.83	0.59 to 1.17	0.2894
Risk in ±36 months of SSc diagnosis	0.81	0.57 to 1.16	0.2565
High titre vs low	0.90	0.63 to 1.27	0.5385
RNAPIII
Overall risk	1.94	1.00 to 3.73	0.0488	1.53	0.60 to 3.88	0.3763
Risk after SSc diagnosis	1.96	0.70 to 5.52	0.2022
Risk in ±36 months of SSc diagnosis	1.97	0.67 to 5.79	0.2160
Scl-70
Overall risk	1.13	0.90 to 1.43	0.2872	1.39	1.08 to 1.80	0.0106
Risk after SSc diagnosis	1.41	1.05 to 1.90	0.0224
Risk in ±36 months of SSc diagnosis	1.23	0.89 to 1.72	0.2113
Centromere
Overall risk	1.28	0.94 to 1.74	0.1116	1.42	0.99 to 2.03	0.0545
Risk after SSc diagnosis	0.95	0.59 to 1.53	0.8324
Risk in ±36 months of SSc diagnosis	1.10	0.67 to 1.81	0.7192
RNP
Overall risk	0.97	0.64 to 1.45	0.8734	0.50	0.23 to 1.09	0.0796
Risk after SSc diagnosis	1.26	0.77 to 2.07	0.3620
Risk in ±36 months of SSc diagnosis	0.90	0.48 to 1.70	0.7414

^aHR was computed adjusting for age, gender, BMI, SES, and smoking status.